December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

8.280 UNCHANGED
Last Price Updated: 8:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
41 42 Next >
News headline image
Cybin Begins Study Using Kernel Flow Headsets To Measure Ketamine's Effects On The Brain ↗
The first study visit to measurethe psychedelic effects of ketamine in the cerebral cortex blood flowis underway, ... 
Via Benzinga
News headline image
Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
News headline image
Revive Therapeutics, Allied Among Top Psychedelic Movers Of Today ↗
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 4.22% at $0.46 
Via Benzinga
News headline image
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Milestone In CYB003 Program ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
News headline image
Cybin Subsidiary Achieves Milestone ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
News headline image
Cybin Planning Pilot Study Of CYB004 ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Milestone in CYB003 Program
Via Investor Brand Network
News headline image
Psychedelic Stock Gainers And Losers From March 29, 2022 ↗
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 9.05% at $5.42 
Via Benzinga
News headline image
Cybin Completes In Vivo Preclinical Studies For Major Depressive Disorder ↗
Cybin Inc.(NYSE: CYBN) announced that its in vivo preclinical studies evaluating the proprietary drug CYB003 are completed. ... 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Significant Milestone Toward Advancing CYB003 Program
Via Investor Brand Network
New Research Reveals How Psychedelics Are Helping Combat Mental Illness
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 29, 2022 – Mental health cases are continuing to rise and are taking a serious toll on the healthcare system. Luckily,... 
Via FinancialNewsMedia
News headline image
Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial
From Cybin Inc.
Via Business Wire
News headline image
Mindset Pharma, Small Pharma Among Top Psychedelic Movers Of Today ↗
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 8.24% at $0.18 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From March 25, 2022 ↗
GAINERS: Allied (OTC: 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) Subsidiary Achieves Milestone
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Subsidiary Achieves Milestone Outlined in Contribution Agreement
Via Investor Brand Network
News headline image
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
News headline image
Allied, Field Trip Health Among Top Psychedelic Movers Of Today ↗
GAINERS: Allied (OTC: 
Via Benzinga
BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Commences Participant Recruitment in Feasibility Study Using Kernel Flow Technology
Via Investor Brand Network
News headline image
Five Companies Developing Second Generation Psychedelics For Mental Health ↗
Along with the psychedelic renaissance came a new type of drug: second generation psychedelics. Developed from classic psychedelics ... 
Via Benzinga
News headline image
Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants
From Cybin Inc.
Via Business Wire
News headline image
Psychedelic Stock Gainers And Losers From March 23, 2022 ↗
GAINERS: Compass Pathways (NASDAQ: 
Via Benzinga
News headline image
Mindset Pharma, Compass Pathways Among Top Psychedelic Movers Of Today ↗
GAINERS: Mind Medicine (NASDAQ: 
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Planning Pilot Study of CYB004
Via Investor Brand Network
Topics Intellectual Property
News headline image
Field Trip Health, Mindset Pharma Among Top Psychedelic Movers Of Today ↗
GAINERS: Field Trip Health (NASDAQ: 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Planning Pilot Study of CYB004, Pursuing Multiple Opportunities to Secure, Support Patent Position for R&D
Via Investor Brand Network
Topics Intellectual Property
News headline image
Psychedelic Compounds-Based Drug Stocks Index Bounces Back ↗
Updating the stock performances of the 13 constituents in our Pure-Play Marijuana and Psychedelic Compounds-Based Drug Stocks Index: up last week but still down 32% YTD. 
Via Talk Markets
News headline image
Field Trip Health, Allied Among Top Psychedelic Movers Of Today ↗
GAINERS: Field Trip Health (NASDAQ: 
Via Benzinga
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) on Leading Edge of Development of Psychedelics as Public Support Grows
Via Investor Brand Network
News headline image
Psychedelic Stock Gainers And Losers From March 16, 2022 ↗
GAINERS: Mindset Pharma (OTC: 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.